Business
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"text","content":"Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022 First patient dosed in Phase 2a trial evaluating tegoprubart in IgA Nephropathy with initial readout expected in late 2022 Successfully completed non-human primate study evaluating tegoprubart monotherapy in the prevention of kidney allograft rejection Conference call today at 4:30 PM ET IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today reported its first quarter 2022 operating and financial results. “We are excited to approach the first of four distinct opportunities to highlight tegoprubart’s broad therapeutic potential this year, beginning with our upcoming ALS readout in June. Based on the growing body of evidence validating the CD40/CD40L pathway, we remain more encouraged than ever in the potential of tegoprubart as a best-in-class anti CD40L antibody,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We continue to make progress across our clinical programs, highlighted by the recent Phase 2a trial initiation in IgAN, and are well positioned to announce meaningful clinical results throughout the remainder of the year.” First Quarter 2022 and Recent Corporate Developments Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart in ALS and remain on track to deliver topline results in June 2022.Dosed the first patient in a Phase 2a clinical trial evaluating tegoprubart for the treatment of IgA Nephropathy. The ongoing trial currently has received regulatory clearances in Australia, New Zealand, Malaysia, and Spain, and the company plans to expand the study in up to seven additional countries in 2022.Successfully completed non-human primate study evaluating tegoprubart monotherapy in the prevention of kidney allograft rejection.Continued progress in two other clinical studies evaluating tegoprubart in kidney transplantation and islet cell transplantation with initial readouts anticipated in late 2022.Hosted first-ever Company R&D Day highlighting tegoprubart with four leading experts on ALS, renal...